LGVN vs. ORMP, TARA, XFOR, IMUX, MRSN, DBVT, CLLS, CTOR, SCLX, and CUE
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Oramed Pharmaceuticals (ORMP), Protara Therapeutics (TARA), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Mersana Therapeutics (MRSN), DBV Technologies (DBVT), Cellectis (CLLS), Citius Oncology (CTOR), Scilex (SCLX), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 19.1% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Longeveron has a consensus target price of $8.67, suggesting a potential upside of 455.56%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Oramed Pharmaceuticals.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Oramed Pharmaceuticals' return on equity of -7.27% beat Longeveron's return on equity.
In the previous week, Longeveron had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Longeveron and 1 mentions for Oramed Pharmaceuticals. Longeveron's average media sentiment score of 1.17 beat Oramed Pharmaceuticals' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.
Oramed Pharmaceuticals has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals received 303 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 72.50% of users gave Oramed Pharmaceuticals an outperform vote.
Oramed Pharmaceuticals has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Summary
Oramed Pharmaceuticals beats Longeveron on 11 of the 19 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LGVN Stock Alerts